February 13, 2017 / 2:36 PM / a year ago

BUZZ-Aeterna Zentaris Inc: Up after growth hormone drug shows promise

** Canadian drug developer’s U.S.-listed shares up 11.5 pct at $3.40

** Says to submit AGHD drug to the U.S. Food and Drug Administration for marketing consideration after drug shows promise in late-stage study

** AGHD or adult growth hormone deficiency occurs when pituitary gland doesn’t produce enough growth hormone, leading to reduced bone strength and lean body mass

** FDA agreed to consider AEZA’s conclusions in a Type A meeting

** Data shows the drug, macrilen, stimulates pituitary gland to produce growth hormone more effectively than a test performed to assess pituitary function

** Aeterna’s Toronto-listed stock up 10.5 pct at C$4.41

** Up to Friday’s close, U.S. stock had lost more than 15 pct of its value YTD

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below